Marianne Stolt-Frostvik
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Journal: Cell death & disease
Published: January 13, 2017
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Journal: BMC cancer
Published: July 27, 2016
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 02, 2015
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 02, 2014
Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 05, 2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Journal: International journal of cancer
Published: June 13, 2014
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Journal: British journal of cancer
Published: March 01, 2014
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.
Journal: BMC clinical pathology
Published: May 29, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026